405 related articles for article (PubMed ID: 29941946)
21. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.
Savolainen MH; Albert K; Airavaara M; Myöhänen TT
Exp Brain Res; 2017 Jul; 235(7):2189-2202. PubMed ID: 28439627
[TBL] [Abstract][Full Text] [Related]
22. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
23. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease.
Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F
J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303
[TBL] [Abstract][Full Text] [Related]
24. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
25. Gender differences and estrogen effects in parkin null mice.
Rodríguez-Navarro JA; Solano RM; Casarejos MJ; Gomez A; Perucho J; de Yébenes JG; Mena MA
J Neurochem; 2008 Sep; 106(5):2143-57. PubMed ID: 18643794
[TBL] [Abstract][Full Text] [Related]
26. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline.
Casarejos MJ; Menéndez J; Solano RM; Rodríguez-Navarro JA; García de Yébenes J; Mena MA
J Neurochem; 2006 May; 97(4):934-46. PubMed ID: 16573651
[TBL] [Abstract][Full Text] [Related]
27. Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease.
Rauschenberger L; Behnke J; Grotemeyer A; Knorr S; Volkmann J; Ip CW
Neurobiol Dis; 2022 Sep; 171():105798. PubMed ID: 35750147
[TBL] [Abstract][Full Text] [Related]
28. Neurodegeneration and contralateral α-synuclein induction after intracerebral α-synuclein injections in the anterior olfactory nucleus of a Parkinson's disease A53T mouse model.
Flores-Cuadrado A; Saiz-Sanchez D; Mohedano-Moriano A; Martinez-Marcos A; Ubeda-Bañon I
Acta Neuropathol Commun; 2019 Apr; 7(1):56. PubMed ID: 30987677
[TBL] [Abstract][Full Text] [Related]
29. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.
Soria FN; Engeln M; Martinez-Vicente M; Glangetas C; López-González MJ; Dovero S; Dehay B; Normand E; Vila M; Favereaux A; Georges F; Lo Bianco C; Bezard E; Fernagut PO
Hum Mol Genet; 2017 Jul; 26(14):2603-2615. PubMed ID: 28520872
[TBL] [Abstract][Full Text] [Related]
30. Peripheral inflammation exacerbates α-synuclein toxicity and neuropathology in Parkinson's models.
La Vitola P; Balducci C; Baroni M; Artioli L; Santamaria G; Castiglioni M; Cerovic M; Colombo L; Caldinelli L; Pollegioni L; Forloni G
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):43-60. PubMed ID: 32696999
[TBL] [Abstract][Full Text] [Related]
31. In utero exposure to dexamethasone causes a persistent and age-dependent exacerbation of the neurotoxic effects and glia activation induced by MDMA in dopaminergic brain regions of C57BL/6J mice.
Costa G; Spulber S; Paci E; Casu MA; Ceccatelli S; Simola N; Morelli M
Neurotoxicology; 2021 Mar; 83():1-13. PubMed ID: 33338551
[TBL] [Abstract][Full Text] [Related]
32. Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease.
Schlachetzki JC; Marxreiter F; Regensburger M; Kulinich A; Winner B; Winkler J
Restor Neurol Neurosci; 2014; 32(4):447-62. PubMed ID: 24604006
[TBL] [Abstract][Full Text] [Related]
33. Time dependent alterations of co-localization of S100beta and GFAP in the MPTP-treated mice.
Himeda T; Watanabe Y; Tounai H; Hayakawa N; Kato H; Araki T
J Neural Transm (Vienna); 2006 Dec; 113(12):1887-94. PubMed ID: 16736245
[TBL] [Abstract][Full Text] [Related]
34. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
[TBL] [Abstract][Full Text] [Related]
35. Dynamic changes of activated AHR in microglia and astrocytes in the substantia nigra-striatum system in an MPTP-induced Parkinson's disease mouse model.
Zhou Y; Zhao WJ; Quan W; Qiao CM; Cui C; Hong H; Shi Y; Niu GY; Zhao LP; Shen YQ
Brain Res Bull; 2021 Nov; 176():174-183. PubMed ID: 34478811
[TBL] [Abstract][Full Text] [Related]
36. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Breckenridge CB; Sturgess NC; Butt M; Wolf JC; Zadory D; Beck M; Mathews JM; Tisdel MO; Minnema D; Travis KZ; Cook AR; Botham PA; Smith LL
Neurotoxicology; 2013 Jul; 37():1-14. PubMed ID: 23523781
[TBL] [Abstract][Full Text] [Related]
38. Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice.
Gu XL; Long CX; Sun L; Xie C; Lin X; Cai H
Mol Brain; 2010 Apr; 3():12. PubMed ID: 20409326
[TBL] [Abstract][Full Text] [Related]
39. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Garau A; Carboni E; Carta AR
Neurotox Res; 2009 Aug; 16(2):127-39. PubMed ID: 19526289
[TBL] [Abstract][Full Text] [Related]
40. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.
Martin LJ; Pan Y; Price AC; Sterling W; Copeland NG; Jenkins NA; Price DL; Lee MK
J Neurosci; 2006 Jan; 26(1):41-50. PubMed ID: 16399671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
